Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
This is a rollover study. Only participants who continue to receive clinical benefit from continuation of SG therapy and are tolerating therapy at the time of enrollment are eligible for this study. Participants enrolled may continue to receive SG at the dose that they were receiving in the Gilead parent study at the time of consenting to participate in this rollover study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study.
Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy.
You may not be if
Females who are pregnant or lactating.
Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated.
Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy.
Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
